A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Trial Profile

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 09 Oct 2014 According to an AstraZeneca media release, detailed results were published in The Lancet Respiratory Medicine.
    • 16 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2014 Primary endpoint has been met according to the AstraZeneca media release. (Time to exacerbation of symptoms)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top